Commerzbank Aktiengesellschaft FI Has $1.12 Million Position in Healthpeak Properties, Inc. $DOC

Commerzbank Aktiengesellschaft FI boosted its stake in shares of Healthpeak Properties, Inc. (NYSE:DOC) by 61.2% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 68,280 shares of the real estate investment trust’s stock after purchasing an additional 25,935 shares during the quarter. Commerzbank Aktiengesellschaft FI’s holdings in Healthpeak Properties were worth $1,122,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in DOC. Norges Bank bought a new position in shares of Healthpeak Properties in the fourth quarter valued at approximately $153,550,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Healthpeak Properties by 694.6% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 8,016,692 shares of the real estate investment trust’s stock worth $153,520,000 after buying an additional 7,007,777 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Healthpeak Properties by 60.3% during the 1st quarter. Bank of New York Mellon Corp now owns 15,456,420 shares of the real estate investment trust’s stock worth $253,949,000 after buying an additional 5,815,189 shares during the period. Fuller & Thaler Asset Management Inc. grew its stake in Healthpeak Properties by 19.2% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 29,648,260 shares of the real estate investment trust’s stock valued at $476,744,000 after buying an additional 4,776,056 shares during the last quarter. Finally, Millennium Management LLC grew its stake in Healthpeak Properties by 235.3% in the 4th quarter. Millennium Management LLC now owns 3,512,223 shares of the real estate investment trust’s stock valued at $56,477,000 after buying an additional 2,464,612 shares during the last quarter. Institutional investors and hedge funds own 93.57% of the company’s stock.

Insider Activity

In other news, insider Scott R. Bohn sold 10,989 shares of the business’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $19.45, for a total transaction of $213,736.05. Following the transaction, the insider owned 7,636 shares in the company, valued at approximately $148,520.20. The trade was a 59.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.23% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently commented on DOC. Scotiabank lifted their target price on shares of Healthpeak Properties from $19.00 to $21.00 and gave the stock a “sector perform” rating in a report on Wednesday, May 27th. Weiss Ratings upgraded shares of Healthpeak Properties from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, May 8th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $22.00 price target (up from $20.00) on shares of Healthpeak Properties in a research report on Thursday, June 11th. Raymond James Financial initiated coverage on Healthpeak Properties in a research note on Wednesday, June 17th. They issued a “market perform” rating on the stock. Finally, Barclays started coverage on Healthpeak Properties in a research report on Tuesday, July 7th. They set an “equal weight” rating and a $23.00 price objective for the company. Four analysts have rated the stock with a Buy rating and fifteen have issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $20.62.

Healthpeak Properties Trading Up 1.4%

Shares of Healthpeak Properties stock opened at $22.59 on Wednesday. The company’s fifty day simple moving average is $20.57 and its 200-day simple moving average is $18.34. The company has a market cap of $15.58 billion, a price-to-earnings ratio of 70.61, a PEG ratio of 3.46 and a beta of 1.02. The company has a current ratio of 2.96, a quick ratio of 2.96 and a debt-to-equity ratio of 1.15. Healthpeak Properties, Inc. has a 1 year low of $15.70 and a 1 year high of $22.72.

Healthpeak Properties (NYSE:DOC) last announced its earnings results on Tuesday, May 5th. The real estate investment trust reported $0.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.43 by $0.02. The business had revenue of $752.95 million for the quarter, compared to analyst estimates of $694.59 million. Healthpeak Properties had a net margin of 7.73% and a return on equity of 2.61%. Healthpeak Properties’s revenue was up 7.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.46 earnings per share. Healthpeak Properties has set its FY 2026 guidance at 1.710-1.750 EPS. As a group, sell-side analysts expect that Healthpeak Properties, Inc. will post 1.75 EPS for the current year.

Healthpeak Properties Dividend Announcement

The business also recently disclosed a monthly dividend, which will be paid on Friday, September 25th. Stockholders of record on Monday, September 14th will be issued a dividend of $0.1017 per share. The ex-dividend date is Monday, September 14th. This represents a c) annualized dividend and a dividend yield of 5.4%. Healthpeak Properties’s payout ratio is presently 381.25%.

About Healthpeak Properties

Healthpeak Properties, Inc is a real estate investment trust (REIT) specializing in healthcare-related real estate. Headquartered in Irvine, California, the company owns, develops and acquires a diversified portfolio of properties that cater to the evolving needs of the healthcare industry. Its investments span life science research facilities, medical office buildings and senior housing communities, positioning Healthpeak as a key provider of specialized real estate assets.

Within its life science segment, Healthpeak develops and leases laboratory and research space to biotechnology, pharmaceutical and other life science companies.